An evaluation of the uptake of Technetium-99m (v) Dimercaptosuccinic acid in patients with squamous carcinoma of the head and neck
- 1 October 1987
- journal article
- research article
- Published by Wiley in Clinical Otolaryngology
- Vol. 12 (6) , 405-411
- https://doi.org/10.1111/j.1365-2273.1987.tb00225.x
Abstract
A new imaging agent, Technetium99m (Tc99m) (v) Dimercaptosuccinic acid (DMSA), has recently been developed which has been used to evaluate head and neck tumours. Twenty-four patients were studied of whom 21 had histologically proven SCC of the head and neck. The remaining 3 had benign lesions. Planar imaging of patients with primary disease revealed a sensitivity of 83% and a 75% specificity. The results of planar imaging of patients with cervical metastases yielded a 92% sensitivity and 100% specificity. Seven patients also had single photon emisson computerized tomography (SPECT) which improved the image quality, spatial resolution and sensitivity of the investigation. Tc99m (v) DMSA imaging provides a cheap and rapid means of investigating head and neck SCC. This study suggests further work is indicated to assess its role in diagnosis and subsequent management.This publication has 5 references indexed in Scilit:
- Imaging of Head and Neck Tumors with Technetium(V)-99m DMSA A New Tumor-Seeking AgentClinical Nuclear Medicine, 1985
- The design of a pentavalent 99mTc− dimercaptosuccinate complex as a tumor imaging agentInternational Journal of Nuclear Medicine and Biology, 1985
- Imaging of Soft Tissue Tumors with Tc(V)-99m Dimercaptosuccinic AcidClinical Nuclear Medicine, 1984
- Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinomaThe Laryngoscope, 1981
- Other Scanning TechniquesPublished by Springer Nature ,1980